BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · Registration

THE LIVINGSTON GROUP FOR TITAN PHARMACEUTICALS

via CHATMAN, LLC

4th Quarter (Oct 1 - Dec 31) · 2018Posted Dec 19, 2018Filing document ↗LDA record ↗

Coverage · Registration filing — establishes the registrant/client relationship. No periodic income or expenses are reported at registration.

Client

Name: THE LIVINGSTON GROUP FOR TITAN PHARMACEUTICALS
Description: Pharmaceutical, makes and markets Probuphine, an implant to treat opioid addiction.
Location: California · United States of America

Registrant

Firm: CHATMAN, LLC
Description: consulting firm
Location: Laurel, Maryland, United States of America

Lobbying activities

4 issues

Defense
FDA labeling change for Probuphine
Lobbyistsms PRISCILLA CHATMAN jd
Veterans
FDA labeling change for Probuphine
Lobbyistsms PRISCILLA CHATMAN jd
Pharmacy
FDA labeling change for Probuphine
Lobbyistsms PRISCILLA CHATMAN jd
Law Enforcement/Crime/Criminal Justice
FDA labeling change for Probuphine
Lobbyistsms PRISCILLA CHATMAN jd

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

THE LIVINGSTON GROUP FOR TITAN… — Receipts Report